Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
these vials are NOT for injection.
If the same vial were diluted with 4mL of water, the concentration would be halved to 2,500mcg/mL, and the same 2,500mcg dose would now require 1mL, or 100 units
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
Gwyer et al., 2019
US$ 26.20
US$ 20.44
US$ 25.26
US$ 25.56
US$ 29.36
US$ 21.39
US$ 28.94
